Beneficial effects of endurance exercise training on skeletal muscle microvasculature in sickle cell disease patients

Angèle N Merlet, Laurent A Messonnier, Cécile Coudy-Gandilhon, Daniel Béchet, Barnabas Gellen, Thomas Rupp, Frédéric Galactéros, Pablo Bartolucci, Léonard Féasson, Angèle N Merlet, Laurent A Messonnier, Cécile Coudy-Gandilhon, Daniel Béchet, Barnabas Gellen, Thomas Rupp, Frédéric Galactéros, Pablo Bartolucci, Léonard Féasson

Abstract

Sickle cell disease (SCD) is a genetic hemoglobinopathy leading to 2 major clinical manifestations: severe chronic hemolytic anemia and iterative vaso-occlusive crises. SCD is also accompanied by profound muscle microvascular remodeling. The beneficial effects of endurance training on microvasculature are widely known. The aim of this study was to evaluate the effects of an endurance training program on microvasculature of skeletal muscle in SCD patients. A biopsy of the vastus lateralis muscle and submaximal incremental exercise was performed before and after the training period. Of the 40 randomized SCD patients, complete data sets from 32 patients were obtained. The training group (n = 15) followed a personalized moderate-intensity endurance training program, while the nontraining (n = 17) group maintained a normal lifestyle. Training consisted of three 40-minute cycle ergometer exercise sessions per week for 8 weeks. Histological analysis highlighted microvascular benefits in the training SCD patients compared with nontraining patients, including increases in capillary density (P = .003), number of capillaries around a fiber (P = .015), and functional exchange surface (P < .0001). Conversely, no significant between-group difference was found in the morphology of capillaries. Indexes of physical ability also improved in the training patients. The moderate-intensity endurance exercise training program improved the muscle capillary network and partly reversed the microvascular defects commonly observed in skeletal muscle of SCD patients. This trial was registered at www.clinicaltrials.gov as #NCT02571088.

© 2019 by The American Society of Hematology.

Source: PubMed

3
订阅